Recoupment suits by particular payors (such as state governments) have enjoyed much success, but class actions on behalf of drug users generally seeking refunds over allegedly faulty pharmaceutical marketing are losing at the class certification stage, because questions of what would have happened with different or no marketing are too individualized. Beck and Herrmann explain.